Healthcare · NYSE/NASDAQ: MCK
MCKESSON CORP
Medical Distribution
Market Cap $91.29B
Verdict: High
Quality Scores
Multi-Bagger
82/100
Compounder Quality
88/100
Management Credibility
88/100
Governance
75/100
Cash Flow Quality
95/100
AI Summary
McKesson Corporation (MCK) demonstrates a formidable market position as a dominant distributor in the US pharmaceutical supply chain. Despite optical volatility in GAAP net income due to significant litigation settlements—specifically the $8.1B opioid settlement—the core business exhibits exceptional top-line scaling, growing from $52.43B to over $400B in a decade. The business model operates on razor-thin margins but compensates with high asset turnover and robust, consistent operating cash flow. Recent years show a strategic pivot toward higher-margin specialty pharmacy and oncology…
Top Opportunities
- Massive revenue scale exceeding $400B
- Consistent and growing Cash Flow from Operations
- Critical infrastructure player in US healthcare
Top Risks
- Razor-thin operating margins below 2%
- Negative Stockholders Equity since 2021
- Massive legacy opioid litigation liabilities
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.